Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Voriconazole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Voriconazole. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-001222-15 Sponsor Protocol Number: 47955 Start Date*: 2014-07-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Bioavailability of voriconazole in critically ill patients
    Medical condition: Suspected or prophylaxis of invasive aspergillosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006633-19 Sponsor Protocol Number: TFF-V2-001 Start Date*: 2022-08-02
    Sponsor Name:TFF Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspe...
    Medical condition: Invasive pulmonary aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000559-42 Sponsor Protocol Number: S54931 Start Date*: 2013-03-01
    Sponsor Name:University Hospitals Leuven
    Full Title: Plasma protein binding characteristics of voriconazole in specific subsets of patients
    Medical condition: Patients suffering from an invasive fungal infection, treated with intravenous or oral voriconazole.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007973-19 Sponsor Protocol Number: VORI-ZonMW Start Date*: 2009-04-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacologic optimization of voriconazole - a prospective clustered group-randomized cross-over trial of therapeutic drug monitoring
    Medical condition: The objective of this prospective stratified cluster randomized cross-over trial is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) res...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001396-37 Sponsor Protocol Number: S52913 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospitals Leuven, Belgium
    Full Title: Determination of voriconazole in saliva - Validation in specifif subsets of patients.
    Medical condition: patients suffering from an invasive fungal infection, treated with intravenous or oral voriconazole.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003479-35 Sponsor Protocol Number: 1 Start Date*: 2006-01-02
    Sponsor Name:Internal Medicine IV, Mecdical University of Vienna
    Full Title: PHARMACOKINETICS OF VORICONAZOLE DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION
    Medical condition: Intensive Care Patients with proven or suspected infection with fungal pathogens requiring parenteral therapy with voricaonzole who are undergoing continuous venovenous hemodiafiltration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000365-35 Sponsor Protocol Number: A1501038 Start Date*: 2004-10-26
    Sponsor Name:Pfizer S.A
    Full Title: Prospective, Open-label, Non-comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) with Voriconazole in Patients with Allogeneic Stem Cell Transplants
    Medical condition: Secondary Prophylaxis of Invasive Fungal Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10049085 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001151-39 Sponsor Protocol Number: A1501081 Start Date*: 2012-03-06
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Adolescents Aged 12 to <17 Years who ar...
    Medical condition: Invasive fungal infections
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002445-20 Sponsor Protocol Number: A8851009 Start Date*: 2007-11-01
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...
    Medical condition: INVASIVE ASPERGILLOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003488 Aspergillosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) IT (Completed) DE (Completed) CZ (Completed) BE (Completed) PT (Completed) GR (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001133-14 Sponsor Protocol Number: A1501088 Start Date*: 2012-03-06
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Children Aged 2 to <12 Years who are at...
    Medical condition: Invasive fungal infections
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004183-38 Sponsor Protocol Number: A1501007 Start Date*: 2015-05-21
    Sponsor Name:Pfizer, Inc.
    Full Title: An open, intravenous multiple dose, multi-centre study to investigate the pharmacokinetics, safety and toleration of Voriconazole in children aged 2-12 years who require treatment for the preventio...
    Medical condition: Systemic Fungal Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000376-41 Sponsor Protocol Number: VORIGENIPHARM Start Date*: 2019-06-18
    Sponsor Name:Fundación de Investigación del Hospital Universitario La Paz (FIBHULP)
    Full Title: Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis.
    Medical condition: Invasive fungal disease in the hematologic patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    20.0 10021881 - Infections and infestations 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    20.0 100000004851 10029355 Neutropenias HLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    20.0 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    20.0 100000004865 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006362-41 Sponsor Protocol Number: RM06/8013 Start Date*: 2007-04-05
    Sponsor Name:Leeds Teaching Hospital NHS Trust
    Full Title: An open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis
    Medical condition: Adult patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011762 Cystic fibrosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021231-14 Sponsor Protocol Number: A1501095 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVA...
    Medical condition: Primary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003488 Aspergillosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) NL (Ongoing) DK (Prematurely Ended) PL (Completed) DE (Prematurely Ended) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-011452-21 Sponsor Protocol Number: Start Date*: 2009-09-18
    Sponsor Name:University Hospitals of Leicester NHS trust
    Full Title: Study of the effectiveness of Voriconazole in the treatment of Aspergillus fumigatus associated asthma
    Medical condition: Asthma with sensitization to aspergillus and isolation in sputum.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000501-20 Sponsor Protocol Number: A1501082 Start Date*: 2017-03-09
    Sponsor Name:Pfizer, Inc.
    Full Title: Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-comparative Study
    Medical condition: Invasive Fungal Infections
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: In utero, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004184-21 Sponsor Protocol Number: A1501037 Start Date*: 2015-05-21
    Sponsor Name:Pfizer, Inc.
    Full Title: An open-label, intravenous to oral switch, multiple dose, multi-centre study to investigate the pharmacokinetics, safety and tolerability of Voriconazole in hospitalized children aged 2 to <12 year...
    Medical condition: Systemic fungal infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-024212-33 Sponsor Protocol Number: CHUBX 2010/36 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de BORDEAUX
    Full Title: Pharmacocinétique de population des anti-infectieux (Ceftazidime, Ciprofloxacine et Voriconazole) chez l’enfant âgé de 1 mois à 5 ans.
    Medical condition: Anti-infectieux en pédiatrie : étude des paramètres pharmacocinétiques de trois anti-infectieux couramment prescrits en pédiatrie et dans des pathologies différentes : mucoviscidose ; infections à...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020953-14 Sponsor Protocol Number: PosaBupreversion1.0 Start Date*: 2010-08-12
    Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital
    Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.
    Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005275-10 Sponsor Protocol Number: A1501080 Start Date*: 2009-03-24
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS...
    Medical condition: Treatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003488 Aspergillosis LLT
    9.1 10051919 Fusarium infection LLT
    9.1 10059045 Scedosporium infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) DE (Completed) BG (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA